Foresee Pharmaceuticals, a Taiwan and US-based biopharmaceutical company and Megapharm Ltd., a leading Israel-based biopharmaceutical company, have entered into an exclusive license and distribution agreement for the commercialisation in Israel and the Palestinian Authority of Foresee’s FP-001 programme, LMIS (Leuprolide Mesylate Injectable Suspension) ready-to-use subcutaneous depot formulations.

Dr. Ben Chien, Founder and executive chairman of Foresee commented: “We are enthusiastic and see a high potential in this new collaboration with Megapharm. They are a key specialty pharma player in their region and have deep commercial expertise and experience in oncology and urology. We entrust them in maximizing FP-001 franchise value in this market well known for its innovation and new product launches. With two commercial partnerships established over the last few months, we are pleased with the momentum in our FP-001 franchise partnering discussions and the quality of partners we are engaging.”

Miron Drucker, CEO and Founder of Megapharm, commented “We are very pleased to have established a partnership with Foresee and look forward to a successful registration and launch of the FP-001 franchise in Israel. The products will provide meaningful advantages and benefits to patients and all medical practice stakeholders.”